JP2019513373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513373A5 JP2019513373A5 JP2018551996A JP2018551996A JP2019513373A5 JP 2019513373 A5 JP2019513373 A5 JP 2019513373A5 JP 2018551996 A JP2018551996 A JP 2018551996A JP 2018551996 A JP2018551996 A JP 2018551996A JP 2019513373 A5 JP2019513373 A5 JP 2019513373A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutical composition
- tumor
- hla
- encoded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022088325A JP7491965B2 (ja) | 2016-03-31 | 2022-05-31 | ネオ抗原およびその使用方法 |
| JP2024080050A JP2024105596A (ja) | 2016-03-31 | 2024-05-16 | ネオ抗原およびその使用方法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316552P | 2016-03-31 | 2016-03-31 | |
| US201662316533P | 2016-03-31 | 2016-03-31 | |
| US201662316530P | 2016-03-31 | 2016-03-31 | |
| US201662316547P | 2016-03-31 | 2016-03-31 | |
| US62/316,552 | 2016-03-31 | ||
| US62/316,530 | 2016-03-31 | ||
| US62/316,533 | 2016-03-31 | ||
| US62/316,547 | 2016-03-31 | ||
| US201662316567P | 2016-04-01 | 2016-04-01 | |
| US201662316571P | 2016-04-01 | 2016-04-01 | |
| US62/316,567 | 2016-04-01 | ||
| US62/316,571 | 2016-04-01 | ||
| PCT/US2017/025462 WO2017173321A1 (en) | 2016-03-31 | 2017-03-31 | Neoantigens and methods of their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088325A Division JP7491965B2 (ja) | 2016-03-31 | 2022-05-31 | ネオ抗原およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513373A JP2019513373A (ja) | 2019-05-30 |
| JP2019513373A5 true JP2019513373A5 (https=) | 2020-05-07 |
Family
ID=59966480
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551996A Withdrawn JP2019513373A (ja) | 2016-03-31 | 2017-03-31 | ネオ抗原およびその使用方法 |
| JP2022088325A Active JP7491965B2 (ja) | 2016-03-31 | 2022-05-31 | ネオ抗原およびその使用方法 |
| JP2024080050A Pending JP2024105596A (ja) | 2016-03-31 | 2024-05-16 | ネオ抗原およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088325A Active JP7491965B2 (ja) | 2016-03-31 | 2022-05-31 | ネオ抗原およびその使用方法 |
| JP2024080050A Pending JP2024105596A (ja) | 2016-03-31 | 2024-05-16 | ネオ抗原およびその使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20190307868A1 (https=) |
| EP (1) | EP3436048B1 (https=) |
| JP (3) | JP2019513373A (https=) |
| KR (2) | KR20220163523A (https=) |
| CN (2) | CN109310739A (https=) |
| AU (4) | AU2017240745B2 (https=) |
| BR (1) | BR112018070183A2 (https=) |
| CA (1) | CA3018748A1 (https=) |
| CO (1) | CO2018011668A2 (https=) |
| CR (1) | CR20180519A (https=) |
| DK (1) | DK3436048T3 (https=) |
| EC (1) | ECSP18082207A (https=) |
| ES (1) | ES3036912T3 (https=) |
| FI (1) | FI3436048T3 (https=) |
| HR (1) | HRP20251095T1 (https=) |
| HU (1) | HUE072805T2 (https=) |
| IL (4) | IL299926B2 (https=) |
| LT (1) | LT3436048T (https=) |
| MA (1) | MA44524A (https=) |
| MX (1) | MX2023001403A (https=) |
| PE (1) | PE20181923A1 (https=) |
| PH (1) | PH12018502047A1 (https=) |
| PL (1) | PL3436048T3 (https=) |
| PT (1) | PT3436048T (https=) |
| RS (1) | RS67172B1 (https=) |
| SG (1) | SG11201808196UA (https=) |
| SI (1) | SI3436048T1 (https=) |
| TW (3) | TWI837869B (https=) |
| WO (1) | WO2017173321A1 (https=) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| IL294183B2 (en) * | 2015-05-20 | 2023-10-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| IL260030B2 (en) | 2016-01-08 | 2025-12-01 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| JP2019513373A (ja) * | 2016-03-31 | 2019-05-30 | ネオン セラピューティクス， インコーポレイテッド | ネオ抗原およびその使用方法 |
| CA3056212A1 (en) | 2016-04-07 | 2017-10-12 | Bostongene Corporation | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| AU2018219862B2 (en) * | 2017-02-07 | 2020-09-17 | Nant Holding IP, LLC | Maximizing T-cell memory and compositions and methods therefor |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Biontech Us Inc. | Protein antigens and uses thereof |
| WO2018187515A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| CN107325172A (zh) * | 2017-07-06 | 2017-11-07 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑2及其在制备治疗非小细胞肺癌的药物中的应用 |
| CN107188956A (zh) * | 2017-07-06 | 2017-09-22 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑4及其在制备治疗非小细胞肺癌的药物中的应用 |
| CN107188957A (zh) * | 2017-07-06 | 2017-09-22 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑1及其在制备治疗非小细胞肺癌的药物中的应用 |
| JP2020534352A (ja) | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| WO2019084538A1 (en) * | 2017-10-27 | 2019-05-02 | Board Of Regents, The University Of Texas System | TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF |
| CN111511392A (zh) | 2017-10-31 | 2020-08-07 | 潘塔希生物科学股份有限公司 | 用于治疗和/或预防肺癌的免疫治疗方法 |
| WO2019094396A1 (en) * | 2017-11-07 | 2019-05-16 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| NZ765655A (en) | 2017-11-27 | 2026-01-30 | Ose Immunotherapeutics | Improved treatment of cancer |
| US11781178B2 (en) | 2017-12-15 | 2023-10-10 | Baylor College Of Medicine | Methods and compositions for the amplification of mRNA |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| WO2019140278A1 (en) * | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
| WO2019147921A1 (en) * | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
| CN108384846B (zh) * | 2018-02-28 | 2020-06-16 | 固安博健生物技术有限公司 | C11orf95基因及其表达产物在诊治类风湿性关节炎和骨关节炎方面的应用 |
| US20210361734A1 (en) | 2018-03-19 | 2021-11-25 | 9 Meters Biopharma, Inc. | Compositions and methods for potentiating immune checkpoint inhibitor therapy |
| EP4252759B1 (en) * | 2018-05-11 | 2025-08-06 | Memorial Sloan Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| WO2019237385A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 用于敲除人TNFSF9基因的gRNA序列及其应用 |
| MX2020014243A (es) * | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| CN112584852A (zh) * | 2018-06-19 | 2021-03-30 | 百欧恩泰美国公司 | 新抗原及其用途 |
| JP7384896B2 (ja) * | 2018-07-22 | 2023-11-21 | ヘルス リサーチ インコーポレイテッド | 主要組織適合遺伝子複合（ｍｈｃ）クラスｉｉ－発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法 |
| WO2020023361A1 (en) | 2018-07-23 | 2020-01-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Enhancing anti-tumor response in melanoma cells with defective sting signaling |
| IL321692A (en) | 2018-07-26 | 2025-08-01 | Curevac Netherlands B V | Cancer vaccines for colorectal cancer |
| IL280113B2 (en) * | 2018-07-26 | 2025-11-01 | Curevac Netherlands B V | Cancer vaccines for uterine cancer |
| WO2020022900A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
| WO2020022903A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER |
| US20220349010A1 (en) * | 2018-07-26 | 2022-11-03 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| CA3106564A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| BR112021001992A2 (pt) * | 2018-08-02 | 2021-05-04 | The Board Of Regents Of The University Of Texas System | efeito adjuvante do agonista tlr1/2 diprovocim sinergiza com anticorpos inibidores de checkpoint para eliminar doença |
| JP2021533777A (ja) | 2018-08-16 | 2021-12-09 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞受容体構築物およびその使用 |
| CN112912387A (zh) * | 2018-08-22 | 2021-06-04 | 弗雷德哈钦森癌症研究中心 | 靶向kras或her2抗原的免疫疗法 |
| JP7598315B2 (ja) * | 2018-09-05 | 2024-12-11 | エンエーセー オンコイミュニティ アクスイェ セルスカプ | 併用療法用ｄｎａワクチンを標的とするネオアンチゲン |
| EP3876971A4 (en) * | 2018-11-06 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | PEPTIDES, COMPOSITIONS AND VACCINES FOR THE TREATMENT OF HYPERMUTATED TUMORS WITH MICROSATELLITE INSTABILITY AND METHODS OF USE THEREOF |
| CN109438570B (zh) * | 2018-11-28 | 2021-07-20 | 生命谷（海南）生物科技股份有限公司 | 肿瘤相关基因fgfr3突变短肽及其应用 |
| US20200190598A1 (en) * | 2018-12-12 | 2020-06-18 | Medimmune, Llc | Blood-based tumor mutation burden predicts overall survival in nsclc |
| KR20210129634A (ko) * | 2018-12-13 | 2021-10-28 | 로드아일랜드하스피틀 | Asph 발현 종양의 성장 및 진행 억제 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020163876A1 (en) * | 2019-02-08 | 2020-08-13 | The Regents Of The University Of California | Compositions and methods involving layilin |
| CA3128081A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| CN114026116A (zh) | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| WO2020176605A1 (en) * | 2019-02-26 | 2020-09-03 | The University Of Vermont And State Agricultural College | Antibodies to neoantigens and uses thereof |
| WO2020176797A1 (en) * | 2019-02-27 | 2020-09-03 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| US20220184191A1 (en) * | 2019-03-11 | 2022-06-16 | Evaxion Biotech A/S | Nucleic acid vaccination using neo-epitope encoding constructs |
| CA3133972A1 (en) * | 2019-03-20 | 2020-09-24 | Turnstone Biologics Inc. | Methods for inducing an immune response against neoantigens |
| JP7668226B2 (ja) * | 2019-03-30 | 2025-04-24 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞組成物を調製するための組成物および方法、ならびにそれらの使用 |
| CN111777677A (zh) * | 2019-04-04 | 2020-10-16 | 天津亨佳生物科技发展有限公司 | 一种egfr t790m 新抗原表位肽及其在治疗肿瘤中的应用 |
| MA55896A (fr) * | 2019-05-07 | 2022-03-16 | Modernatx Inc | Polynucléotides servant à perturber l'activité de cellule immunitaire et procédés pour les utiliser |
| CN110201418B (zh) * | 2019-05-09 | 2020-10-27 | 西安交通大学 | 一种基于固定化SNAP-tag融合蛋白的细胞膜色谱柱及其制备方法 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| WO2020252039A1 (en) * | 2019-06-12 | 2020-12-17 | Biontech Us Inc. | Neoantigen compositions and uses thereof |
| US12486334B2 (en) * | 2019-07-12 | 2025-12-02 | The Regents Of The University Of California | Chemically controlled monoclonal antibody target engagement |
| EP4004054A4 (en) | 2019-07-26 | 2023-10-25 | Yuhan Corporation | ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODIES AND ITS APPLICATION |
| CN114450306B (zh) * | 2019-07-26 | 2024-04-05 | Abl生物公司 | 抗egfr/抗4-1bb双特异性抗体及其用途 |
| JP2022543583A (ja) * | 2019-07-30 | 2022-10-13 | ブレイクバイオ コーポレイション | 固形腫瘍の治療方法 |
| US20220307013A1 (en) * | 2019-08-30 | 2022-09-29 | The Regents Of The University Of California | Gene fragment overexpression screening methodologies, and uses thereof |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| EP4041293A1 (en) * | 2019-10-10 | 2022-08-17 | PACT Pharma, Inc. | Method of treating immunotherapy non-responders with an autologous cell therapy |
| WO2021092095A1 (en) * | 2019-11-04 | 2021-05-14 | Gritstone Oncology, Inc. | Neoantigen vaccine therapy |
| EP4056197A4 (en) * | 2019-11-07 | 2023-09-06 | Shenzhen Gino Biotechnology Co., Ltd. | TUMOR-SPECIFIC POLYPEPTIDE SEQUENCE AND USE THEREOF |
| JP2023523664A (ja) * | 2019-11-18 | 2023-06-07 | エピヴァックス セラピューティクス インコーポレイテッド | 改善されたネオエピトープワクチン及びがんを治療するための方法 |
| KR102410556B1 (ko) * | 2020-01-16 | 2022-06-20 | 아주대학교산학협력단 | 미토콘드리아 타겟팅용 펩타이드 |
| KR102397922B1 (ko) * | 2020-02-19 | 2022-05-13 | 서울대학교 산학협력단 | 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도 |
| KR102159921B1 (ko) * | 2020-03-24 | 2020-09-25 | 주식회사 테라젠바이오 | 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
| CN111729084B (zh) * | 2020-04-30 | 2021-05-11 | 南京北恒生物科技有限公司 | Sting激动剂与工程化免疫细胞的组合疗法 |
| US11130787B2 (en) * | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| US11977057B2 (en) * | 2020-06-13 | 2024-05-07 | Complete Omics International Inc. | Method and system for neoantigen analysis |
| WO2021259963A1 (en) | 2020-06-23 | 2021-12-30 | Pandora Endocrine Innovation B.V. | Immunization against wnt4 for treatment and prophylaxis of breast cancer |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN116438308A (zh) * | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| CN112023062A (zh) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | 一个用可溶性IgE受体抑制过敏反应的方法 |
| WO2022077007A1 (en) * | 2020-10-06 | 2022-04-14 | The Regents Of The University Of California | Motif neoepitopes for cancer immunotherapy |
| TW202231292A (zh) | 2020-10-13 | 2022-08-16 | 美商健生生物科技公司 | 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法 |
| WO2022099157A1 (en) * | 2020-11-06 | 2022-05-12 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| EP4255465A4 (en) * | 2020-12-07 | 2025-02-26 | Iogenetics, LLC. | Bystander protein vaccines |
| US20240091359A1 (en) * | 2021-01-28 | 2024-03-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Novel esr1 derived peptides and uses thereof for neoantigen therapy |
| US20240299520A1 (en) * | 2021-02-09 | 2024-09-12 | Virginia Commonwealth University | Mini circular rna therapeutics and vaccines and methods of use thereof |
| WO2022179568A1 (en) * | 2021-02-25 | 2022-09-01 | Westlake Therapeutics (Hangzhou) Co., Limited | Neoantigenic peptide and its use for treating braf gene mutation related diseases |
| CN113173985A (zh) * | 2021-03-24 | 2021-07-27 | 深圳市新靶向生物科技有限公司 | 一种与结直肠癌驱动基因突变相关的抗原肽及其应用 |
| JP2024516542A (ja) * | 2021-04-06 | 2024-04-16 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｍｈｃクラスｉペプチドを含む方法および組成物 |
| WO2022226055A1 (en) * | 2021-04-22 | 2022-10-27 | Iogenetics, Llc | Personalized allogeneic immunotherapy |
| US20240358808A1 (en) * | 2021-04-23 | 2024-10-31 | Flow Pharma, Inc. | Vaccine for sars-cov-2 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| US20240226147A1 (en) * | 2021-05-06 | 2024-07-11 | Astrin Biosciences Inc. | Trojan circulating tumor cells |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| US20240424094A1 (en) * | 2021-10-06 | 2024-12-26 | CancerVAX Inc. | Methods and compositions for cancer treatment |
| US20250026818A1 (en) | 2021-10-19 | 2025-01-23 | Sciencemed Spóka z ograniczon odpowiedzialnoci | Male contraception |
| CN114478712B (zh) * | 2022-03-29 | 2022-09-23 | 深圳吉诺因生物科技有限公司 | Hpv抗原表位及其鉴定方法、应用 |
| CN114605499B (zh) * | 2022-04-07 | 2023-06-23 | 华中科技大学同济医学院附属协和医院 | 一种可拮抗rbsm1蛋白rna结合活性的多肽rip-18及其应用 |
| WO2023215579A1 (en) * | 2022-05-06 | 2023-11-09 | The Children's Medical Center Corporation | Anaplastic lymphoma kinase (alk) cancer vaccines and methods of use thereof |
| KR20240017325A (ko) * | 2022-07-29 | 2024-02-07 | 주식회사 엘지화학 | 항원 전달용 재조합 융합 단백질 및 이의 이용 |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024102764A1 (en) * | 2022-11-07 | 2024-05-16 | The Wistar Institute Of Anatomy And Biology | Compositions comprising neoantigens and methods of enhancing anti-pd1 therapy |
| EP4644410A1 (en) * | 2022-12-30 | 2025-11-05 | Lg Chem, Ltd. | Recombinant fusion protein having modified cysteine residue for antigen delivery and uses thereof |
| WO2024148183A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer |
| WO2024148185A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*11:01 in lung cancer |
| WO2024148181A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*11:01 in lung cancer |
| WO2024148178A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer |
| WO2024215872A1 (en) * | 2023-04-11 | 2024-10-17 | The Regents Of The University Of California | Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma |
| EP4724458A2 (en) * | 2023-06-07 | 2026-04-15 | The Regents of the University of California | Peptide therapeutics |
| WO2025024603A2 (en) * | 2023-07-25 | 2025-01-30 | Elaine Tsiumas Kaznessis | Personalized bacterial cancer vaccines |
| WO2025028960A1 (ko) * | 2023-07-28 | 2025-02-06 | 주식회사 엘지화학 | 항원 전달용 컨쥬게이트 및 이의 이용 |
| CN116970058B (zh) * | 2023-09-22 | 2023-12-15 | 成都朗谷生物科技股份有限公司 | 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用 |
| GB202400424D0 (en) * | 2024-01-11 | 2024-02-28 | Cancer Research Tech Ltd | Treatment and prevention of lung cancer |
| WO2025168848A1 (en) | 2024-02-09 | 2025-08-14 | IMMUNEO Therapeutics GmbH | Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0452457B1 (en) | 1989-11-03 | 1997-08-20 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| WO1994003205A1 (en) | 1992-08-07 | 1994-02-17 | Cytel Corporation | Hla binding peptides and their uses |
| BR9406652A (pt) | 1993-03-05 | 1996-09-10 | Cytel Corp | Composição |
| US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
| DE69435171D1 (de) | 1993-09-14 | 2009-01-08 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
| US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
| US7255862B1 (en) | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1015619A1 (en) | 1997-09-19 | 2000-07-05 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
| ATE440951T1 (de) * | 1997-12-17 | 2009-09-15 | Serono Genetics Inst Sa | Verlängerte cdns, die für sekretierte proteine kodieren |
| US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| JP2002523045A (ja) * | 1998-08-21 | 2002-07-30 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒトｒｎａ関連タンパク質 |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
| DK1180159T3 (da) | 1999-05-28 | 2008-11-17 | Targeted Genetics Corp | Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser |
| US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| CA2343602A1 (en) * | 2000-04-18 | 2001-10-18 | Genset | Est's and encoded human proteins |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| JP5191729B2 (ja) | 2004-03-11 | 2013-05-08 | フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート |
| MX2007010008A (es) | 2005-02-16 | 2008-01-18 | Lentigen Corp | Vectores lentivirales y su uso. |
| UY29460A1 (es) | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| EP1760089B1 (en) * | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| SI1806358T1 (sl) * | 2005-09-05 | 2010-06-30 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II |
| TWI596109B (zh) * | 2007-02-21 | 2017-08-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| US8501167B2 (en) * | 2007-03-19 | 2013-08-06 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| EP2071334A1 (en) * | 2007-12-14 | 2009-06-17 | Transmedi SA | Compositions and methods of detecting TIABS |
| US20110165566A1 (en) * | 2009-07-09 | 2011-07-07 | Wittliff James L | Methods of optimizing treatment of breast cancer |
| EP2493921B1 (en) | 2009-10-30 | 2018-09-26 | Albumedix Ltd | Albumin variants |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| EP2678448A4 (en) * | 2011-02-22 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | CIRCULATING BIOMARKERS |
| WO2012121429A1 (ko) * | 2011-03-07 | 2012-09-13 | 연세대학교 산학협력단 | 암 세포 바이오 마커를 동정하는 방법 및 상기 방법으로 동정한 nmd-무관 암 세포 바이오 마커 |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| WO2012177925A1 (en) * | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| WO2014180490A1 (en) * | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| US20190099475A1 (en) * | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| BR112017022845A2 (pt) | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
| IL294183B2 (en) * | 2015-05-20 | 2023-10-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| JP2016028025A (ja) * | 2015-07-29 | 2016-02-25 | ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ | がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ） |
| GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| CN108884468A (zh) * | 2016-01-27 | 2018-11-23 | 阿德瓦希斯公司 | 基于个性化递送载体的免疫疗法及其用途 |
| JP2019513373A (ja) * | 2016-03-31 | 2019-05-30 | ネオン セラピューティクス， インコーポレイテッド | ネオ抗原およびその使用方法 |
-
2017
- 2017-03-31 JP JP2018551996A patent/JP2019513373A/ja not_active Withdrawn
- 2017-03-31 DK DK17776811.6T patent/DK3436048T3/da active
- 2017-03-31 SI SI201731623T patent/SI3436048T1/sl unknown
- 2017-03-31 HU HUE17776811A patent/HUE072805T2/hu unknown
- 2017-03-31 ES ES17776811T patent/ES3036912T3/es active Active
- 2017-03-31 MA MA044524A patent/MA44524A/fr unknown
- 2017-03-31 TW TW111138089A patent/TWI837869B/zh active
- 2017-03-31 TW TW106111296A patent/TWI781928B/zh active
- 2017-03-31 CR CR20180519A patent/CR20180519A/es unknown
- 2017-03-31 EP EP17776811.6A patent/EP3436048B1/en active Active
- 2017-03-31 PT PT177768116T patent/PT3436048T/pt unknown
- 2017-03-31 TW TW113107104A patent/TW202440616A/zh unknown
- 2017-03-31 CN CN201780034080.4A patent/CN109310739A/zh active Pending
- 2017-03-31 LT LTEPPCT/US2017/025462T patent/LT3436048T/lt unknown
- 2017-03-31 RS RS20250878A patent/RS67172B1/sr unknown
- 2017-03-31 PE PE2018001918A patent/PE20181923A1/es not_active Application Discontinuation
- 2017-03-31 HR HRP20251095TT patent/HRP20251095T1/hr unknown
- 2017-03-31 CA CA3018748A patent/CA3018748A1/en active Pending
- 2017-03-31 KR KR1020227041564A patent/KR20220163523A/ko not_active Ceased
- 2017-03-31 FI FIEP17776811.6T patent/FI3436048T3/fi active
- 2017-03-31 IL IL299926A patent/IL299926B2/en unknown
- 2017-03-31 SG SG11201808196UA patent/SG11201808196UA/en unknown
- 2017-03-31 AU AU2017240745A patent/AU2017240745B2/en active Active
- 2017-03-31 PL PL17776811.6T patent/PL3436048T3/pl unknown
- 2017-03-31 BR BR112018070183-1A patent/BR112018070183A2/pt not_active Application Discontinuation
- 2017-03-31 US US16/094,851 patent/US20190307868A1/en not_active Abandoned
- 2017-03-31 WO PCT/US2017/025462 patent/WO2017173321A1/en not_active Ceased
- 2017-03-31 CN CN202211177112.5A patent/CN115558030A/zh active Pending
- 2017-03-31 KR KR1020187031742A patent/KR20180129899A/ko not_active Ceased
-
2018
- 2018-09-20 IL IL261880A patent/IL261880B/en unknown
- 2018-09-24 PH PH12018502047A patent/PH12018502047A1/en unknown
- 2018-09-28 MX MX2023001403A patent/MX2023001403A/es unknown
- 2018-10-29 CO CONC2018/0011668A patent/CO2018011668A2/es unknown
- 2018-10-31 EC ECSENADI201882207A patent/ECSP18082207A/es unknown
-
2021
- 2021-11-15 AU AU2021269272A patent/AU2021269272B2/en active Active
-
2022
- 2022-04-10 IL IL292094A patent/IL292094B2/en unknown
- 2022-05-31 JP JP2022088325A patent/JP7491965B2/ja active Active
-
2023
- 2023-05-02 US US18/311,158 patent/US20230414735A1/en active Pending
- 2023-05-02 US US18/311,155 patent/US20230405102A1/en active Pending
- 2023-10-05 AU AU2023241320A patent/AU2023241320B2/en active Active
-
2024
- 2024-05-16 JP JP2024080050A patent/JP2024105596A/ja active Pending
-
2025
- 2025-09-29 IL IL323656A patent/IL323656A/en unknown
- 2025-09-30 AU AU2025242131A patent/AU2025242131A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513373A5 (https=) | ||
| Butterfield et al. | Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations | |
| JP7731705B2 (ja) | Ｎａｎｔ癌ワクチン | |
| Ganesh et al. | Immunotherapy in colorectal cancer: rationale, challenges and potential | |
| Saab et al. | Insights into lung cancer immune-based biology, prevention, and treatment | |
| Bauer et al. | The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma | |
| Veatch et al. | Endogenous CD4+ T cells recognize neoantigens in lung cancer patients, including recurrent oncogenic KRAS and ERBB2 (Her2) driver mutations | |
| Moehler et al. | Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives | |
| van der Burg et al. | Vaccines for established cancer: overcoming the challenges posed by immune evasion | |
| WO2020072700A1 (en) | Hla single allele lines | |
| Wang et al. | Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and-independent adoptive immunotherapies | |
| TW202134430A (zh) | 腫瘤細胞疫苗 | |
| KR20180038550A (ko) | 다양한 암의 면역요법 치료에서의 사용을 위한 신규 펩티드, 펩티드의 조합 및 골격 | |
| TWI787500B (zh) | 新抗原表位疫苗及免疫刺激組合物及方法 | |
| IL292864A (en) | New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer | |
| Chatani et al. | Mutated RAS: targeting the “untargetable” with T cells | |
| TW201811822A (zh) | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 | |
| Khleif et al. | Cancer vaccines as enablers of immunotherapy | |
| US20210172961A1 (en) | Methods for identifying rna editing-derived epitopes that elicit immune responses in cancer | |
| Drakes et al. | Lymph node–targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumors | |
| JP2019509265A (ja) | 二重標的化によるアデノウイルスの皮下送達 | |
| TWI750644B (zh) | 用於對抗多種癌症的免疫療法的新胜肽及胜肽組合 | |
| JP2021532122A (ja) | 癌のための個別化ワクチン | |
| Jafferji et al. | Adoptive T-cell therapy for solid malignancies | |
| US20200352972A1 (en) | Aldoxorubicin combination treatments and methods |